FDA panel to review Merck HIV treatment

Share this article:

The FDA is scheduled to convene a panel of outside experts to review Merck's developmental HIV treatment Isentress on Sept. 5.

Merck is seeking approval to market Isentress to HIV patients who have stopped responding to at least one drug in each of the three available classes of oral antiretroviral therapies.

If approved, Isentress would be the first in a new class of antiretroviral agents called integrase inhibitors that inhibit the insertion of HIV DNA into human DNA. Inhibiting integrase from performing this function blocks the ability of the virus to replicate and infect new cells. There are drugs in use that inhibit two other enzymes critical to the HIV replication process - protease and reverse transcriptase - but currently no approved drugs inhibit integrase.

Last month, the FDA granted Merck’s Isentress application priority review status, indicating the drug addresses an urgent medical need. As a result, Isentress’ review time was "fast-tracked" to six months, instead of the 10 months the process often takes under standard review.

Merck is expecting a final decision on Isentress by mid-October.

Approximately 1 million people in the US are HIV positive, according to statistics from the Centers for Disease Control.

Share this article:

Email Newsletters

More in News

BI rethinks hepatitis business, posts 2013 results

BI rethinks hepatitis business, posts 2013 results

Boehringer Ingelheim says it is no longer pursuing an interferon-free combination of faldaprevir and deleobuvir.

Roche wraps quarter with two fewer pipeline medications

Roche wraps quarter with two fewer pipeline medications

Roche also announced first-quarter sales shrank 1%.

2013 favored specialists, specialty Rx

2013 favored specialists, specialty Rx

The latest IMS Institute for Healthcare Informatics assessment of 2013's prescription drug use shows that 2.3% of prescriptions account for 30% of a patient's out-of-pocket prescription costs.